Biotech Values

[dav1234]

GSK heart treatment fails in Phase III trial
GSK's (GSK) darapladib treatment failed to reduce the risk of heart attack or stroke among chronic-heart-disease patients in the first of two Phase III trials.
GSK acquired the rights to darapladib when it bought Human Genome Sciences for $3B in 2012.
In the study of over 1,500 patients, darapladib was no better than a placebo in cutting the time prior to a heart attack, stroke or death.
However, darapladib did bring about a reduction in some coronary events, although GSK didn't provide details.
Analyst Savvas Neophytou expects GSK to take a writedown of £150M ($239M) in Q4 because of the failure of darapladib.
Shares are -2.2% premarket


http://www.gsk.com/media/press-releases/2013/gsk-announces-top-line-results-from-pivotal-phase-iii-study-of-d.html